What is the clinical evidence from this study?

Study design: Other. Population: Cardiac hypertrophy in hypertension. Intervention: Losartan vs. Hydralazine and normotensive rats. Primary outcome: Cardiac hypertrophy and MAP kinase (JNK, ERK, p38) activities.

What question did this study set out to answer?

This research investigates how the AT1 receptor affects JNK activity during cardiac hypertrophy in hypertensive rats.

October 1, 2000Hypertension

Important Role of Angiotensin II–Mediated c-Jun NH2-Terminal Kinase Activation in Cardiac Hypertrophy in Hypertensive Rats

View Full Paper

Ask AI

Bookmark

Key result

Losartan prevented and regressed cardiac hypertrophy in stroke-prone spontaneously hypertensive rats, accompanied by reduced JNK and AP-1 activity, whereas hydralazine did not.

Why the study?

Does AT1 receptor antagonism with losartan prevent cardiac hypertrophy and reduce JNK activity in hypertensive rats?

Population

Stroke-prone spontaneously hypertensive rats (SHRSP) and normotensive rats

Comparison

Losartan (AT1 receptor antagonist) or hydralazine vs Untreated SHRSP and normotensive rats

Design

Preclinical

Authors

YIYasukatsu IzumiOsaka Metropolitan University SKShokei KimOtsuka (Japan)YZYumei ZhanKunming University of Science and Technology

Discussion

Member takes

Implication

Does not inform clinical hypertension management; leaves open human translation of AT1-specific hypertrophy effects.

Key Points

This research investigates how the AT1 receptor affects JNK activity during cardiac hypertrophy in hypertensive rats.
Examined cardiac MAP kinase activities in stroke-prone spontaneously hypertensive rats (SHRSP) during hypertrophy phases.
Used losartan, an AT1 receptor antagonist, to assess effects on cardiac hypertrophy and JNK activity.
Compared effects of losartan and hydralazine on cardiac function and MAP kinase activities in SHRSP.
Losartan prevented and regressed cardiac hypertrophy in SHRSP, reducing JNK and AP-1 activity.
Hydralazine normalized blood pressure but did not affect cardiac hypertrophy or JNK/AP-1 activities, instead increasing cardiac ERK activity.
Cardiac JNK activities were significantly elevated in SHRSP compared to normotensive rats.

Structured PICO

Does AT1 receptor antagonism with losartan prevent cardiac hypertrophy and reduce JNK activity in hypertensive rats?

Population

Stroke-prone spontaneously hypertensive rats (SHRSP) and normotensive rats

Intervention

Losartan (AT1 receptor antagonist) or hydralazine

Comparator

Untreated SHRSP and normotensive rats

Outcome

Cardiac hypertrophy and MAP kinase activities (JNK, ERK, p38)surrogate

AT1 receptor antagonism with losartan prevents and regresses cardiac hypertrophy in hypertensive rats by reducing JNK and AP-1 activity, an effect independent of blood pressure lowering alone.

Cite This Study

Izumi et al. (2000) studied Cardiac hypertrophy in hypertension. Losartan vs. Hydralazine and normotensive rats was evaluated on Cardiac hypertrophy and MAP kinase (JNK, ERK, p38) activities. Losartan prevented and regressed cardiac hypertrophy in stroke-prone spontaneously hypertensive rats, accompanied by reduced JNK and AP-1 activity, whereas hydralazine did not.

synapsesocial.com/papers/6a216039baff55cd04030a41 https://doi.org/10.1161/01.hyp.36.4.511

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Important Role of Angiotensin II–Mediated c-Jun NH2-Terminal Kinase Activation in Cardiac Hypertrophy in Hypertensive Rats

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Important Role of Angiotensin II–Mediated c-Jun NH2-Terminal Kinase Activation in Cardiac Hypertrophy in Hypertensive Rats

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider